Brand and Other Names:Osphena
Dosing & Uses
Dosage Forms & Strengths
Estrogen agonist/antagonist indicated for treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
60 mg PO qDay with food
Renal impairment: No dosage adjustment required
Mild-to-moderate hepatic impairment: No dosage adjustment required
Severe hepatic impairment: Not studied; do not use
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Hot flush (7.5%)
Vaginal discharge (3.8%)
Muscle spasms (3.2%)
Genital discharge (1.3%)
Black Box Warnings
- Elicits estrogenic agonistic effects in the endometrium Increased risk of endometrial cancer in women with a uterus who uses unopposed estrogens (ie, without a progestin to reduce endometrial hyperplasia)
- Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding
- Increased risk of stroke and DVT reported in postmenopausal women who received daily oral conjugated estrogens [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative study
- In ospemifene clinical trials, the incidence of DVT was 1.45 per thousand women with ospemifene 60 mg compared with 1.04 per thousand women taking placebo
Undiagnosed abnormal genital bleeding
Known or suspected estrogen-dependent neoplasia
History of, or active DVT or PE History of, or active arterial thromboembolic disease (eg, stroke, MI)
Known or suspected pregnancy or women who may become pregnant
Documented hypersensitivity to drug or ingredients
Manage cardiovascular disorders, arterial vascular disease (eg, hypertension, DM, smoking, hypercholesterolemia, obesity), and/or venous thromboembolism to reduce risk for progression to serious disease
Increased risk for endometrial hyperplasia (see Black Box Warnings)
Has not been studied in women with breast cancer; do not use with known or suspected breast cancer or history of breast cancer
Do not use with severe hepatic impairment (not studied)
Ospemifene is primarily metabolized by CYP3A4 and CYP2C9; CYP2C19 also contributes to its metabolism; avoid moderate-to-strong inhibitors of these isoenzymes as they may increase risk of adverse effects
May initiate or increase occurrence of hot flashes in some women
Pregnancy & Lactation
Pregnancy Category: X
Lactation: Unknown whether distributed in human breast milk; do not breastfeed
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Estrogen agonist/antagonist with tissue selective effects; its biological actions are mediated through binding to estrogen receptors resulting in activation of estrogenic pathways in some tissues and blockade in others
Peak plasma time: 2 hr (fasted); 2.5 hr (high fat/high calorie meal)
Peak plasma concentration: 533 ng/mL (fasted); 1198 ng/mL (high fat/high calorie meal)
AUC: 4165 ng•h/mL (fasted); 7521 ng•h/mL (high fat/high calorie meal)
Protein bound: >99%
Vd: 448 L
Metabolized by CYP3A4, CYP2C9, and CYP2C19
Half-life: 26 hr
Total body clearance: 9.16 L/hr
Excretion: 75% feces, 7% urine
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs